Unibest
← Back to patent-cliff list

CAS 415697-58-4

(2-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)phenyl)boronic acid

Codes: SPAR-004

Application context (from source-drug indications)

局灶性节段性肾小球硬化症Sparsentan免疫球蛋白a肾病Sparsentan抗中性粒细胞胞浆抗体相关性血管炎SparsentanKidney diseaseSparsentanAlport 综合征Sparsentan过敏性紫癜Sparsentan

Source drugs (routes using this intermediate)

DrugTierExpiry
SparsentanTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.

SupplierProductPrice bandMOQLead timeQualificationsAction
Qualified Partner — East China API Works(2-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)phenyl)boronic acid
Pharmaceutical Intermediates
On requestOn requestOn request
—

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.